Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04431635
Title Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Big Ten Cancer Research Consortium

follicular lymphoma

marginal zone B-cell lymphoma


Copanlisib + Nivolumab + Rituximab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.